News & Trends - Biotechnology

BCG anti-TB vaccine trial for COVID-19 protection

Health Industry Hub | June 24, 2020 |
[Total: 1    Average: 4/5]

Five hundred front line healthcare workers and paramedics in NSW will join an international trial, to discover whether the tuberculosis (TB) vaccine reduces the impact of COVID-19.

A number of Australian healthcare workers have been infected with coronavirus already, while ongoing personal protective equipment (PPE) shortages have left doctors and nurses vulnerable.

Health Minister Brad Hazzard said he is delighted the NSW Health Services Union (HSU) is supporting the trial with a $350,000 contribution and that so many health staff are taking part.

“This virus is not going away any time soon, so until we have a proven vaccine, trials like this alongside daily testing and COVID-safe behaviours, are vitally important,” Mr Hazzard said.

“Our front line health workers risk exposure to COVID-19 every day, so the sooner we can find a breakthrough and fingers crossed it is the BCG anti-TB vaccine, the better for all of us.”

HSU NSW Secretary Gerard Hayes said the decision to help fund the study was a straightforward one because if the vaccine proves successful, the benefits will be enormous.

“We have to use every tool available to protect our cleaners, security officers, paramedics, therapists and other hospital workers against the severity of COVID which is why we are so enthusiastically supporting this trial,” Mr Hayes said.

“It may seem unusual for us to fund a program such as this, but we know our duty of care to members extends beyond wages and conditions to include their health and wellbeing.”

Dr Rama Kandasamy, Staff Specialist in Immunisation at Sydney Children’s Hospitals Network said the 12 month trial will be rolled out in several hospitals over the coming weeks.

“Workers have already been vaccinated at The Children’s Hospital Westmead and staff at Westmead Hospital, Sydney Children’s Hospital, Randwick, Prince of Wales Hospital and St Vincent’s Hospital will follow,” Dr Kandasamy said.

“Half the participants will receive the BCG vaccine and the other half will receive a placebo and they will be monitored to see if they contract COVID and the severity of their symptoms.

“This trial sets the scene for us to be at the forefront of COVID-19 specific vaccine trials and the results could be the key to providing at-risk groups early protection.”

The BRACE trial was initially launched by Murdoch Children’s Research Institute (MCRI). NSW healthcare workers and paramedics are among 10,000 across Australia along with other countries including Spain and The Netherlands, to participate in the trial.


About the author

About the author

The Health Industry Hub is Australia’s first & only One Stop Hub for the Life Sciences industry (Pharma, Medtech and Biotech) that connects the healthcare community and its key stakeholders through centralised and meaningful content, facilitates engagement and inspiration for collaboration to shape the future and enhance patient outcomes. Health Industry Hub" class="more" title="Link to full profile">Link to full profile

News & Trends - Medical Technology

MedTech News - Private health insurer looking to invest in Australian private hospitals

Private health insurer looking to invest in Australian private hospitals

Health Industry Hub | July 15, 2020 |

MedTech News: In a recent opinion piece Dr Bill Coote, former AMA Secretary General and former Director of the Medicare […]

More


News & Trends - Pharmaceuticals

Pharma News - Merck Australia supports the first Australian-developed COVID-19 vaccine - Sypharma and Vaxine

Merck Australia supports the first Australian-developed COVID-19 vaccine

Health Industry Hub | July 15, 2020 |

Pharma News: Sypharma, an Australian biopharmaceutical formulation company, announced manufacturing of COVAX-19 and Advax adjuvant for Covid-19 in partnership with […]

More


News & Trends - Pharmaceuticals

Pharma News - Precision prescribing to combat Australia’s expected surge in mental illness

Precision prescribing to combat Australia’s expected surge in mental illness

Health Industry Hub | July 15, 2020 |

Pharma News: COVID-19 social isolation, familial and community disconnection, shock, job loss and health fears create the perfect storm for […]

More


Medical

Medical Pharma Biotech MedTech - $47M accelerator program for MedTech, Biotech and Pharma sectors in diabetes and cardiovascular disease

$47M accelerator program for MedTech, Biotech and Pharma sectors in diabetes and cardiovascular disease

Health Industry Hub | July 15, 2020 |

Medical News: The operation of the Australian Government’s $47 million Targeted Translation Research Accelerator (TTRA) initiative for diabetes and cardiovascular […]

More